281-647-7766
Visit Us410 West Grand Parkway South
Suite #4C, Katy, TX 77494
Suite #4C, Katy, TX 77494
Office HoursMon – Thu: 8:30 AM – 5:00 PM
Fri: 8:30 – 4:00 · Sat: 9:00 – 1:00
Fri: 8:30 – 4:00 · Sat: 9:00 – 1:00
281-647-7766
Home/Cancer Types/Prostate Cancer
Board-certified medical oncologists Dr. Shagufta Naqvi and Dr. Mohammad Riaz treat advanced, recurrent and high-risk prostate cancer with hormone therapy, next-generation androgen receptor drugs, chemotherapy, PARP inhibitors and radioligand therapy, working alongside your urologist and radiation oncologist. We care for men from Katy, Memorial, Sugar Land and across Greater Houston.
Overview
Prostate cancer is cancer that starts in the prostate, a walnut-sized gland below the bladder that makes part of the seminal fluid. Almost all prostate cancers are adenocarcinomas. Many grow very slowly and may never cause harm, while others are aggressive and can spread to lymph nodes and bones.
Doctors describe how aggressive a prostate cancer is using the Gleason score and Grade Group (1 to 5), the PSA level and the clinical stage. Together these place the cancer in a risk group, from very low to very high risk, which guides whether to monitor, treat locally or treat the whole body.
| Grade Group | Gleason score | What it means |
|---|---|---|
| 1 | 6 | Low grade; often suitable for active surveillance. |
| 2–3 | 7 | Intermediate grade; usually treated, depending on other factors. |
| 4–5 | 8–10 | High grade; more likely to grow and spread; needs active treatment. |
Early prostate cancer usually causes no symptoms. When symptoms occur, they can include trouble urinating, a weak or interrupted stream, needing to urinate often especially at night, blood in the urine or semen, and erectile dysfunction. Bone pain in the back, hips or ribs can be a sign that cancer has spread.
Most urinary symptoms are caused by benign prostate enlargement (BPH), not cancer, but they should still be checked by a doctor.
The main risk factors for prostate cancer are older age, Black race, and a family history of prostate cancer, especially a father or brother diagnosed before 65. Inherited mutations such as BRCA2, BRCA1 and Lynch syndrome genes also raise risk. Black men are more likely to develop prostate cancer and about twice as likely to die from it.
| Risk factor | What to know |
|---|---|
| Age | About 6 in 10 cases are diagnosed in men 65 or older. |
| Race | Black men have higher incidence and about twice the mortality and should consider earlier screening. |
| Family history | A father or brother with prostate cancer more than doubles risk. |
| Inherited mutations | BRCA2, BRCA1, ATM, CHEK2 and Lynch syndrome genes. Results can also open treatment options such as PARP inhibitors. |
| Lifestyle | Obesity and smoking are linked to more aggressive disease. |
PSA screening is a personal decision made with your doctor. The U.S. Preventive Services Task Force recommends that men ages 55 to 69 discuss the benefits and risks of PSA testing. The American Cancer Society recommends this conversation at 50 for average-risk men, at 45 for Black men and men with a close relative diagnosed before 65, and at 40 for men at even higher risk.
Prostate cancer is staged from I to IV using tumor size (T), lymph node spread (N), metastasis (M), the PSA level and the Grade Group. Stages I and II are confined to the prostate, stage III has grown beyond it or is very high grade, and stage IV has spread to lymph nodes, bones or other organs.
| Stage | What it means | Common treatment approach |
|---|---|---|
| Stage I | Small, low-grade cancer confined to the prostate with a low PSA. | Active surveillance for most; surgery or radiation for some. |
| Stage II | Confined to the prostate but larger, higher grade or higher PSA. | Surgery or radiation; short-term hormone therapy with radiation for intermediate risk; surveillance for selected favorable cases. |
| Stage III | Locally advanced, growing outside the prostate, or very high grade or PSA. | Radiation with long-term hormone therapy, sometimes plus abiraterone, or surgery as part of combined treatment. |
| Stage IV | Spread to lymph nodes, bones or other organs. | Hormone therapy combined with an androgen receptor pathway inhibitor, with or without docetaxel; radiation for symptoms; later options include PARP inhibitors, Lu-177 PSMA therapy and radium-223. |
| Stage at diagnosis (SEER) | What it means | 5-year relative survival |
|---|---|---|
| Localized | No sign of spread outside the prostate | >99% |
| Regional | Spread to nearby structures or lymph nodes | >99% |
| Distant | Spread to bones, lungs, liver or distant nodes | 38% |
| All stages combined | 98% |
Source: American Cancer Society, based on NCI SEER data. These averages cannot predict any one man’s outcome, and treatment for advanced prostate cancer continues to improve.
Prostate cancer that keeps growing despite testosterone-lowering hormone therapy is called castration-resistant prostate cancer (CRPC). Metastatic prostate cancer has spread beyond the prostate, most often to the bones. Both are managed by a medical oncologist with a sequence of systemic treatments that can control the disease for years.
Premier Oncology Consultants provides the systemic treatments for prostate cancer, including hormone therapy, androgen receptor pathway inhibitors, chemotherapy, PARP inhibitors and coordination of radioligand therapy, plus palliative care. We work closely with urologists and radiation oncologists for surgery, radiation and active surveillance.
Your plan is built around your risk group, stage, PSA trend and genetic results. We explain every option, coordinate with your urologist and radiation oncologist, and deliver treatment in a comfortable, supportive setting close to home.
Leuprolide, degarelix, relugolix and similar drugs lower testosterone, which fuels prostate cancer growth.
Used for: High-risk, recurrent and metastatic disease
Abiraterone, enzalutamide, apalutamide and darolutamide block testosterone signaling and extend survival.
Used for: Advanced and castration-resistant cancer
Docetaxel and cabazitaxel, used for metastatic hormone-sensitive and castration-resistant prostate cancer.
Used for: Metastatic prostate cancer
Olaparib and related drugs for cancers with BRCA or other DNA-repair gene mutations.
Used for: mCRPC with DNA-repair mutations
Lu-177 PSMA-617 for PSMA-positive mCRPC and radium-223 for bone metastases, coordinated with nuclear medicine.
Used for: Metastatic castration-resistant cancer
Led by Dr. Riaz, who completed a Palliative Medicine Fellowship at the Cleveland Clinic. We manage bone pain, fatigue, hot flashes and the effects of hormone therapy.
Used for: All stages, alongside treatment
Learn more about chemotherapy at Premier Oncology and our full range of cancer treatment services.
Hormone therapy can cause hot flashes, fatigue, loss of libido, weight gain, muscle and bone loss and mood changes. Surgery and radiation can affect urinary and erectile function. Exercise, bone-protecting medicines, careful monitoring and supportive care reduce most of these effects.
Our biopsychosocial approach addresses physical, emotional and practical needs together: we monitor bone density, heart health and blood sugar during long-term hormone therapy, encourage strength training, treat pain and fatigue, and support partners and families.
There is no proven way to prevent prostate cancer, but staying at a healthy weight, being physically active, not smoking and eating a diet rich in vegetables may lower the risk of aggressive disease. The most important step is an informed conversation with your doctor about PSA screening at the right age for your risk.
Board-Certified Medical Oncologist
Dr. Naqvi brings years of experience treating a wide range of cancers with a focus on personalized medicine, patient advocacy and compassionate care.
Board-Certified Medical Oncologist & Palliative Care Specialist
Dr. Riaz completed a Palliative Medicine Fellowship at the Cleveland Clinic, so patients receive cutting-edge cancer therapy while keeping the highest possible quality of life.
Our oncology office is located at 410 West Grand Parkway South, Suite #4C, Katy, TX 77494, with easy access from I-10 and the Grand Parkway. Patients come to us for prostate cancer care from Katy, Cinco Ranch, Fulshear, Richmond, Sugar Land, Memorial, the Energy Corridor, West Houston and communities throughout Greater Houston.
Hours: Monday–Thursday 8:30 AM–5:00 PM · Friday 8:30 AM–4:00 PM · Saturday 9:00 AM–1:00 PM
Phone: 281-647-7766 · Fax: 281-647-7767 · Map & directions
Yes. Prostate cancer that has not spread beyond the prostate or nearby tissue is very often curable with surgery or radiation, and the 5-year relative survival rate is above 99%. Metastatic prostate cancer is usually not curable but can often be controlled for many years.
There is no single normal PSA. Levels rise with age and prostate size, and many doctors investigate further when PSA is above about 4 ng/mL or rising quickly. An elevated PSA does not mean cancer, and MRI often helps decide whether a biopsy is needed.
Active surveillance means monitoring low-risk prostate cancer with regular PSA tests, MRI and repeat biopsies instead of treating right away. Treatment starts only if the cancer shows signs of growing, which avoids side effects for many men.
The 5-year relative survival rate for prostate cancer that has spread to distant parts of the body is about 38%, according to the American Cancer Society. Newer hormone drugs, PARP inhibitors and Lu-177 PSMA therapy continue to improve outcomes.
A medical oncologist treats prostate cancer with medicines such as hormone therapy, androgen receptor pathway inhibitors, chemotherapy, PARP inhibitors and radioligand therapy, especially for high-risk, recurrent and metastatic disease, and coordinates care with your urologist and radiation oncologist.
It depends on the situation. With radiation for intermediate-risk cancer, hormone therapy often lasts 4 to 6 months; for high-risk cancer, 18 months to 3 years; for metastatic disease it is usually continued long-term.
Yes. The American Cancer Society recommends that Black men talk with their doctor about PSA screening starting at age 45, because they have a higher risk of developing and dying from prostate cancer.
Premier Oncology Consultants offers same-day appointments for newly diagnosed patients at our Katy office. Call 281-647-7766 to schedule.
Yes. A second opinion can review your risk group, PSMA PET results and genetic testing, and explain newer systemic options. We see men from Katy, Memorial, Sugar Land and across Greater Houston.
We accept most major insurance plans, including AARP, Aetna, Aetna Medicare, Amerigroup Star Plus, Amerivantage, Blue Cross Blue Shield of Texas, Blue Medicare Advantage PPO, UnitedHealthcare, Tricare and TMHP. Self-pay patients are welcome. Call 281-647-7766 to verify coverage.
Sources
This page is for education only and does not replace medical advice from your own physician. Treatment decisions should be made with your care team based on your individual diagnosis.
Same-Day Appointments in Katy
Rising PSA, a new diagnosis, or cancer that is no longer responding to hormone therapy? Our board-certified oncologists will review your results and build a plan with you, often on the same day you call.
Same-Day Appointments · Katy, TX
Share your details and our Katy team will call you back, usually the same business day.
Please do not include detailed medical information. Your details are used only to contact you about your appointment.